Literature DB >> 16276340

Survival of candida sepsis in extracorporeal membrane oxygenation.

Mary S Minette1, Laura M Ibsen.   

Abstract

OBJECTIVE: To report the survival of fungal sepsis in extracorporeal membrane oxygenation.
DESIGN: Single case report.
SETTING: Tertiary referral children's hospital pediatric intensive care unit. PATIENTS: A single case report of an infant with congenital heart disease who developed candida sepsis while supported postoperatively with extracorporeal membrane oxygenation.
RESULTS: This infant survived a prolonged episode of candidemia after repair of congenital heart disease, which required extracorporeal membrane oxygenation support. The patient has no identified sequelae at 6-month follow-up and continues on long-term fluconazole therapy for candida endocarditis.
CONCLUSIONS: Candidemia, particularly Candida albicans species, may not be a contraindication for extracorporeal membrane oxygenation support. With antifungal therapy and adequate inotropic use to counter the effects of septicemia, survival can be maintained until the patient adequately recovers, allowing decannulation, removal of all catheters, and eventual bloodstream sterility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16276340     DOI: 10.1097/01.pcc.0000165563.61181.fb

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  2 in total

1.  The morbidity and mortality of patients with fungal infections before and during extracorporeal membrane oxygenation support.

Authors:  Thomas Pluim; Natasha Halasa; Sharon E Phillips; Geoffrey Fleming
Journal:  Pediatr Crit Care Med       Date:  2012-09       Impact factor: 3.624

2.  Outcomes of pediatric patients with abdominal sepsis requiring surgery and extracorporeal membrane oxygenation using the Extracorporeal Life Support Organization database.

Authors:  Michael R Phillips; Amal L Khoury; Briana J K Stephenson; Lloyd J Edwards; Anthony G Charles; Sean E McLean
Journal:  Am Surg       Date:  2015-03       Impact factor: 0.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.